Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 3
2002 3
2003 7
2004 11
2005 32
2006 35
2007 33
2008 25
2009 20
2010 20
2011 15
2012 16
2013 14
2014 8
2015 12
2016 15
2017 11
2018 7
2019 3
2020 19
2021 11
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

292 results
Results by year
Filters applied: . Clear all
Page 1
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S. Matsuyama S, et al. J Virol. 2020 Dec 9;95(1):e01648-20. doi: 10.1128/JVI.01648-20. Print 2020 Dec 9. J Virol. 2020. PMID: 33055254 Free PMC article.
Of note, ciclesonide suppressed the replication of all these mutants by 90% or more, suggesting that these mutants cannot completely overcome ciclesonide blockade. ...Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. ...
Of note, ciclesonide suppressed the replication of all these mutants by 90% or more, suggesting that these mutants cannot completely …
Local and systemic safety of intranasal corticosteroids.
Sastre J, Mosges R. Sastre J, et al. J Investig Allergol Clin Immunol. 2012;22(1):1-12. J Investig Allergol Clin Immunol. 2012. PMID: 22448448 Free article. Review.
A review of the published literature indicates that the side effect profiles of INCs consist primarily of a low incidence of mostly mild and often transient local AEs, such as nasal irritation and epistaxis.The second-generation INC agents currently in use (mometasone furoate nas …
A review of the published literature indicates that the side effect profiles of INCs consist primarily of a low incidence of mostly mild and …
Ciclesonide.
Reynolds NA, Scott LJ. Reynolds NA, et al. Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005. Drugs. 2004. PMID: 14977388 Clinical Trial.
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown....
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of …
Ciclesonide and the treatment of asthma.
Korenblat PE. Korenblat PE. Expert Opin Pharmacother. 2010 Feb;11(3):463-79. doi: 10.1517/14656560903575647. Expert Opin Pharmacother. 2010. PMID: 20102309 Review.
Moreover, studies have found that ciclesonide is as effective as other ICSs in establishing and controlling disease symptoms. Controlled clinical trials also showed that ciclesonide is associated with minimal systemic and local treatment-related adverse events. ...
Moreover, studies have found that ciclesonide is as effective as other ICSs in establishing and controlling disease symptoms. Control …
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Jeon S, et al. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20. doi: 10.1128/AAC.00819-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366720 Free PMC article.
Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects....
Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and c
The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide.
Meltzer EO, Derendorf H. Meltzer EO, et al. Ann Allergy Asthma Immunol. 2006 Aug;97(2):149-57. doi: 10.1016/S1081-1206(10)60005-1. Ann Allergy Asthma Immunol. 2006. PMID: 16937743 Review.
OBJECTIVE: To review the potential systemic activity of ciclesonide and its active metabolite, desisobutyryl-ciclesonide, by evaluation of the effects on hypothalamic-pituitary-adrenal (HPA) axis function. DATA SOURCES: EMBASE and MEDLINE searches using the keyword …
OBJECTIVE: To review the potential systemic activity of ciclesonide and its active metabolite, desisobutyryl-ciclesonide, by e …
Ciclesonide versus other inhaled corticosteroids for chronic asthma in children.
Kramer S, Rottier BL, Scholten RJ, Boluyt N. Kramer S, et al. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD010352. doi: 10.1002/14651858.CD010352. Cochrane Database Syst Rev. 2013. PMID: 23450613 Free article. Review.
SELECTION CRITERIA: Randomised controlled parallel or cross-over studies were eligible for the review. We included studies comparing ciclesonide with other corticosteroids both at nominally equivalent doses or lower doses of ciclesonide. ...There is a need for studi …
SELECTION CRITERIA: Randomised controlled parallel or cross-over studies were eligible for the review. We included studies comparing cicl
Different types of intranasal steroids for chronic rhinosinusitis.
Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Chong LY, et al. Cochrane Database Syst Rev. 2016 Apr 26;4:CD011993. doi: 10.1002/14651858.CD011993.pub2. Cochrane Database Syst Rev. 2016. PMID: 27115215 Free article. Review.
SELECTION CRITERIA: Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing first-generation intranasal corticosteroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) with second-generation intranasal co …
SELECTION CRITERIA: Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing first-generation intranas …
Ciclesonide--a novel corticosteroid for the management of asthma.
Chopra D, Bhandari B, Wardhan N. Chopra D, et al. Curr Clin Pharmacol. 2012 May;7(2):73-7. doi: 10.2174/157488412800228901. Curr Clin Pharmacol. 2012. PMID: 22283615 Review.
Ciclesonide is a corticosteroid with unique pharmacological profile including a high degree of serum protein binding, a low oral bioavailability and rapid systemic elimination. Ciclesonide is a prodrug metabolized by esterases to desisobutyryl ciclesonide (de
Ciclesonide is a corticosteroid with unique pharmacological profile including a high degree of serum protein binding, a low oral bioa
292 results